APT Therapeutics Overview
- Year Founded
-
2001
- Status
-
Private
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.58M
- Investors
-
4
APT Therapeutics General Information
Description
Developer of antiplatelet therapy designed for acute myocardial infarction, stroke and transplantation complications. The company's therapy uses protein engineering, protein informatics and cheminformatics software to create base therapeutics and molecule drugs for thrombotic diseases, enabling patients to get minimally damaged in case of a heart attack.
Contact Information
Website
apt-therapeutics.comCorporate Office
- Saint Louis, MO
- United States
Corporate Office
- Saint Louis, MO
- United States
APT Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Grant | 01-May-2023 | $1.58M | Completed | Generating Revenue | ||
| 11. Grant | 20-Sep-2021 | Completed | Generating Revenue | |||
| 10. Grant | 15-Sep-2020 | Completed | Generating Revenue | |||
| 9. Grant | 18-Sep-2019 | Completed | Generating Revenue | |||
| 8. Grant | 18-Apr-2017 | Completed | Generating Revenue | |||
| 7. Grant | 18-Apr-2017 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 27-Jan-2017 | Completed | Generating Revenue | |||
| 5. Grant | 01-Aug-2014 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Jan-2005 | $3.68M | Completed | Startup | ||
| 3. Early Stage VC | 08-Jul-2004 | $2.08M | $3.68M | Completed | Startup |
APT Therapeutics Patents
APT Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4114443-B1 | Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis | Active | 06-Mar-2020 | ||
| EP-4114443-C0 | Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis | Active | 06-Mar-2020 | ||
| ES-3062461-T3 | Composition comprising apyrase and annexin that binds phosphatidylserine for treatment of arterial and venous thrombosis | Active | 06-Mar-2020 | ||
| AU-2021230101-A1 | Synergistic and targeting compositions for treatment of arterial and venous thrombosis | Active | 06-Mar-2020 | ||
| AU-2021230101-B2 | Synergistic and targeting compositions for treatment of arterial and venous thrombosis | Active | 06-Mar-2020 | C12N9/14 |
APT Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | |||
| CID Equity | Venture Capital | Minority | ||
| Prolog Ventures | Venture Capital | Minority | ||
| Nidus Center for Scientific Enterprise | Accelerator/Incubator | Minority |
APT Therapeutics FAQs
-
When was APT Therapeutics founded?
APT Therapeutics was founded in 2001.
-
Where is APT Therapeutics headquartered?
APT Therapeutics is headquartered in Saint Louis, MO.
-
What industry is APT Therapeutics in?
APT Therapeutics’s primary industry is Drug Discovery.
-
Is APT Therapeutics a private or public company?
APT Therapeutics is a Private company.
-
What is APT Therapeutics’s current revenue?
The current revenue for APT Therapeutics is .
-
How much funding has APT Therapeutics raised over time?
APT Therapeutics has raised $3.68M.
-
Who are APT Therapeutics’s investors?
U.S. Department of Health and Human Services, CID Equity, Prolog Ventures, and Nidus Center for Scientific Enterprise have invested in APT Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process